STL Index for: Trifarotene

Discover how trifarotene, a fourth-generation retinoid, effectively treats acne and post-inflammatory hyperpigmentation (PIH). Learn about its benefits, clinical evidence, and role in managing acne sequelae.

Review of the effectiveness of trifarotene, a novel retinoid, in managing atrophic acne scars, highlighting its targeted action on retinoid acid receptor gamma (RAR-γ) and presenting recent clinical data supporting its use as a valuable adjunct treatment for acne scarring.

Topical retinoids are recommended as first-line therapy for most patients with acne. Tazarotene 0.045% lotion is a novel formulation that utilizes polymeric emulsion technology to improve tolerability and epidermal penetration.

This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

A new topical retinoid, trifarotene, the first fourth-generation retinoid, is now available in Canada for the treatment of moderate facial and truncal acne.

In two large randomized vehicle-controlled 12-week trials and in a 52-week open label study of moderate-to-severe acne at the face and trunk in subjects aged 9 years and older, trifarotene 50 μg/g cream demonstrated efficacy, safety, and cutaneous tolerability.

A variety of new skin treatments introduced in 2019.

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)